RxDoctor Payments Data

Muhammad Salam, MD

Endocrinology, Diabetes & Metabolism · Kansas City, MONPI 1689802381

Payments from drug & device makers

$228in general payments, 2019–2025

Across 14 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$61
  • Abbott$28
  • Alnylam Pharmaceuticals Inc.$21
  • Amgen$20
  • Medtronic$20
  • AstraZeneca$18
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$21695%
  • Education$125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$228 in reported general payments places this provider in the 20th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri

Medicare billing

Part B allowed, 2024
$207,203
Medicare patients
196
Services billed
7,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$91,119
MounjaroTirzepatide61$73,507
JardianceEmpagliflozin73$57,319
FarxigaDapagliflozin Propanediol21$20,330
JanuviaSitagliptin Phosphate11$13,143
Tresiba Flextouch U-100Insulin Degludec21$9,663
Humalog Kwikpen U-100Insulin Lispro16$4,429
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,133
Novolog FlexpenInsulin Aspart14$3,967
Nano 2nd Gen Pen NeedlePen Needle, Diabetic20$2,508
Metformin Hcl ErMetformin Hcl51$869
Testosterone Cypionate22$664
Levothyroxine Sodium72$506
Alendronate Sodium66$422
Atorvastatin Calcium18$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$91,11982 claims
Lilly USA, LLCMounjaro$61$73,50761 claims
AstraZenecaFarxiga$18$20,33021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →